Reimbursement Responsibility. The Lessee/Owner Parties shall reimburse the Operating Agent for all Capital Costs and Operating Costs it incurs in connection and consistent with this Agreement, pursuant to the sharing principles described in this Article IX, except to the extent (i) a Party (including the Operating Agent) is solely responsible for the costs under this Agreement or the Agreement otherwise limits the Operating Agent’s right to reimbursement of such costs, or (ii) in the future it is determined by mutual agreement of all the Parties, or by Dispute resolution pursuant to Article XX upon any issue raised by any Party, that operation of any particular provision is inequitable under the circumstances at the time, in which case the Operating Agent shall be reimbursed the amounts in question pending resolution of the Dispute and shall thereafter refund such amount as determined by such Dispute resolution, together with interest at the True-Up Interest Rate over the actual number of days elapsed from the payment by the Lessee/Owner Party to the date of such refund.
Reimbursement Responsibility. The Lessee/Owner Parties shall reimburse the Operating Agent for all Capital Costs and Operating Costs it incurs in connection and consistent with this Agreement in accordance with the Unit 1 O&M Agreement and the Unit 2 O&M Agreement.
Reimbursement Responsibility. Monogram will use Commercially Reasonable Efforts to obtain Coverage from payers in the US Territory for the Commercial Assay at its own [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. risk and expense promptly following Regulatory Approval of the Pfizer Product in the US Territory, which efforts shall include attempts to obtain applicable CPT codes for the Commercial Assays. Pfizer shall have no obligation to seek to obtain Coverage from payers in the US Territory or to compensate Monogram with respect to Commercial Assays sold to Third Parties in the US Territory, but will provide reasonable assistance if Monogram encounters difficulty in obtaining reimbursements with respect to payers to the extent the JSC determines such assistance is necessary, at Monogram’s expense. Reports regarding Monogram’s reimbursement status and plans for the Commercial Assay in the US Territory will be provided to the JSC on a quarterly basis.
Reimbursement Responsibility. Pfizer shall be fully responsible for obtaining any reimbursement and pricing from payers, including Reimbursement Approvals, at its own expense and risk, in any Ex-US Country. Monogram will reasonably cooperate with Pfizer and consolidation partners in obtaining any Reimbursement Approvals in such countries, at Pfizer’s expense. Monogram will be fully subrogated to Pfizer with respect to the right to receive reimbursement or other payment from Third Parties for Commercial Assays performed in respect of Samples originating in the Ex-US Territory. In the event that a Third Party makes a payment to Monogram in respect of a Commercial Assay performed in respect of a Sample originating in the Ex-US Territory, Monogram shall promptly remit such amount to Pfizer.
